Sign up USA
Proactive Investors - Run By Investors For Investors

Regeneron higher after key drugs help deliver market-beating fourth quarter

The company’s key drugs – Praluent and Dupixent, and sales of Eyelea in the US – helped to lift the numbers for the quarter
eye drops
The company is anticipating additional pipeline progress in 2018

Regeneron Pharmaceuticals Inc.(NASDAQ:REGN) saw its shares gain traction in early trade after the company recorded fourth-quarter numbers that beat market expectations.

The company’s key drugs – Praluent and Dupixent, and sales of Eyelea in the US – helped to lift the numbers for the quarter.

Quarterly and 2017 hit by new tax reform

In a statement, the company said earnings dropped to US$174mln or US$1.50 per share, from the US$253mln, or US$2.19 per share a year ago.

Adjusted earnings-per-share came in at US$5.23, against market expectations for US$4.48.

During the period, revenue rose to US$1.58bn from US$1.23bn, and well above market expectations for US$1.50bn.

Regeneron recorded a US$326.2mln charge related to the new tax legislation, which hit the fourth quarter and the full year 2017 effective tax rates.

Leonard S. Schleifer, president and CEO said: "We are anticipating additional pipeline progress in 2018, including regulatory decisions for dupilumab in uncontrolled asthma and cemiplimab in advanced cutaneous squamous cell carcinoma, cardiovascular outcomes data for Praluent, as well as Phase 3 data for EYLEA in diabetic retinopathy."

Its shares were up 2.35% at US$342.54.

View full REGN profile View Profile

Regeneron Pharmaceuticals Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use